AIMS: To investigate sodium hyaluronate (SH) efficacy in the treatment of pregnancy rhinitis. METHODS: A single-center, prospective, open-label, 2 parallel-group study was carried out. Pregnant women affected by pregnancy rhinitis were randomly assigned to 1 of 2 groups: Group A was treated with SH, while Group B did not receive any treatment. Pregnancy rhinitis symptoms and quality of life (QOL) during pregnancy were investigated by administering a questionnaire and carrying out an otorhinolaryngoiatric visit. RESULTS: A significant reduction in the intensity of headache, snoring and insomnia in the Group A compared to the Group B were demonstrated. In the Group A, a significant lower presence of amount of secretions (Group A 0.88, 95% CI 0.57-1.18 vs. Group B 2.00, 95% CI 1.69-2.31, p < 0.001), turbinate hypertrophy (Group A 1.70, 95% CI 1.46-1.94 vs. Group B 2.53, 95% CI 2.29-2.77, p < 0.001), and mucosal congestion/hyperemia (Group A 1.41, 95% CI 1.14-1.68 vs. Group B 2.26, 95% CI 1.99-2.53, p < 0.001) was observed. No adverse events were reported in patients treated with SH. CONCLUSIONS: SH is a safe and effective therapeutic alternative for the treatment of pregnancy rhinitis symptoms, improving patients' QOL.
No takes yet. Share an insight, caveat, or question.
Favilli et al. (2018) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: